EUVIMEDEUVIMED entdecken
Crossref

Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization

Yanli Wang iD, Yongle Wang, Wei Zhang, Yulong Xu iD, Nilay S Narayan, Hua Cheng iD, Hongzhi Yang iD, Yafei Huang, Can Zhang iD, Changning Wang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yanli Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Charlestown, Mas…. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Brain, Pyruvate Kinase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting pyruvate kinase M2 (PKM2) offers a route to probe neuroinflammatory metabolism in Alzheimer’s disease (AD). We report the radiosynthesis and preclinical evaluation of a PKM2-targeted PET radioligand, [11C]7d. [11C]7d was produced in 21.6–29.4% decay-corrected yield from trapped [11C]CH3I with >95% radiochemical purity. Whole-body PET (0–60 min) indicated predominantly hepatobiliary clearance with modest renal excretion. In wild-type mice, [11C]7d showed rapid brain entry followed by washout consistent with reversible kinetics. Pharmacological pretreatment with 7d reduced whole-brain AUC, indicating displaceable binding. Ex vivo autoradiography showed a 62.8% signal reduction with 7d and ∼20.1% higher binding in 5xFAD versus NonTg sections. In vivo, 5xFAD mice displayed higher uptake; cerebellum normalized SUVR(20–60 min) increased across multiple regions. PKM2 immunohistochemistry supported regional target engagement. These data support [11C]7d as a tool for noninvasive visualization of PKM2-linked glycolytic alterations in the living brain and motivate further quantitative and translational studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePositron-Emission TomographyBrainPyruvate KinaseRadiopharmaceuticalsAnimalsMiceHumansLigandsMaleMice, TransgenicTissue Distribution

Substanzen

Pyruvate KinaseRadiopharmaceuticalsLigandsPkm protein, mouse

Autor:innen und Institutionen

  • Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, United States.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass…
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.

ORCID-Profile: Yanli Wang, Yulong Xu, Hua Cheng, Hongzhi Yang, Can Zhang, Changning Wang

Förderung

  • National Institutes of Health

Zitieren

APA

Wang, Y., Wang, Y., Zhang, W., Xu, Y., Narayan, N. S., Cheng, H., Yang, H., Huang, Y., Zhang, C., & Wang, C. (2025). Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02549

Vancouver

Wang Y, Wang Y, Zhang W, Xu Y, Narayan NS, Cheng H, et al. Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02549

BibTeX
@article{Wang2025,
  author = {Wang, Yanli and Wang, Yongle and Zhang, Wei and Xu, Yulong and Narayan, Nilay S and Cheng, Hua and Yang, Hongzhi and Huang, Yafei and Zhang, Can and Wang, Changning},
  title = {Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02549}
}
Kostenlos starten →